Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: Analysis in western patients after curative-intent surgery

Table 2 Univariate and multivariate analysis for disease-free survival and overall survival-including the Cancer Genome Atlas subgroups

Disease-free survival	Univariate			Multivariate
Variables	HR	95%CI	P value	HR	95%CI	P value
Male (vs female)	0.93	0.59-1.46	0.745	─	─	─
Age > 65 (vs < 65 yr)	1.52	0.95-2.45	0.082	─	─	─
Charlson < 5 (vs ≥ 5)	0.65	0.40-1.05	0.076	─	─	─
Total Gastrectomy (vs subtotal)	2.33	1.49-3.62	< 0.001	1.8	1.12-2.88	0.015
Diffuse/mixed (vs others)	1.80	1.15-2.83	0.011	1.24	0.78-1.97	0.367
pT3/pT4 status (vs pT1/pT2)	10.87	4.72-24.98	< 0.001	5.64	2.33-13.64	< 0.001
pN+ (vs pN0)	7.56	3.77-15.15	< 0.001	3.25	1.54-6.80	0.002
CMT (vs none)	1.28	0.82-1.98	0.280	─	─	─
TCGA Classification
GS	1	─	─	─	─	─
EBV	0.42	0.17-1.06	0.068	0.37	0.14-0.94	0.037
MSI	0.21	0.09-0.52	0.001	0.31	0.13-0.76	0.010
CIN	0.43	0.21-0.84	0.014	0.43	0.22-0.87	0.018
Overall survival	Univariate			Multivariate
Variables	HR	95%CI	P value	HR	95%CI	P value
Male (vs female)	1.08	0.72-1.63	0.708	─	─	─
Age > 65 (vs < 65 yr)	1.16	0.77-1.74	0.483	─	─	─
Charlson < 5 (vs ≥ 5)	1.16	0.84-1.88	0.273	─	─	─
Total Gastrectomy (vs subtotal)	1.90	1.27-2.84	0.002	1.7	1.11-2.60	0.014
Diffuse/mixed (vs others)	1.56	1.04-2.34	0.032	1.16	0.77-1.77	0.765
pT3/pT4 status (vs pT1/pT2)	4.50	2.59-7.82	< 0.001	3.23	1.74-5.97	< 0.001
pN+ (vs pN0)	3.29	2.02-5.35	< 0.001	1.69	0.98-2.92	0.061
CMT (vs none)	0.96	0.64-1.44	0.841	─	─	─
TCGA Classification
GS	1	─	─	─	─	─
EBV	0.33	0.13-0.82	0.017	0.27	0.10-0.68	0.006
MSI	0.27	0.12-0.61	0.001	0.35	0.15-0.78	0.01
CIN	0.46	0.24-0.88	0.019	0.47	0.25-0.91	0.025

CI: Confidence interval; CIN: Chromosomal instability; CMT: Chemotherapy; EBV: Epstein-Barr virus; GS: Genomically stable; HR: Hazard ratio; MSI: Microsatellite instability.